Elvinix chases disease-modifying type 1 diabetes therapy with Zealand peptides
The licensed dual-agonist peptide portfolio will be developed to alter disease course rather than only manage glucose.
PR
By Priya Raman · Science Reporter
Sep 16 10:11 ETSource: BioBuzz
The wire
- 01Elvinix licensed Zealand Pharma's dual-agonist peptide portfolio to pursue a disease-modifying type 1 diabetes therapy.
- 02Disease modification in type 1 diabetes remains an unmet goal beyond insulin replacement.
- 03Clinical development stage and financial terms were not disclosed in the report.
From the source
Read at news.google.comElvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes